Product Description
A small molecule and a naphthyridine analogue with antineoplastic activity. Vosaroxin intercalates into DNA in a site-specific manner and blocks the re-ligation process carried out by topoisomerase II during DNA replication. As a result, inhibition of DNA replication, RNA and protein synthesis occurs, followed by cell cycle arrest at G2 phase and induced p53-independent apoptosis. This agent shows a favorable toxicity profile in several aspects: it does not generate reactive oxygen species, as do anthracyclines, hence reducing the risk of cardiotoxicity; it is not a P-glycoprotein (P-gp) substrate, and thereby evades the common mechanism for multidrug resistance; and it has limited distribution to normal tissues and a more chemically stable molecular structure. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/vosaroxin)
Mechanisms of Action: TOP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Viracta Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Acute Myeloid Leukemia
Phase 2: Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia|Small Cell Lung Cancer|Non-Small-Cell Lung Cancer|Sarcoma, Myeloid|Ovarian Cancer|Anemia, Refractory, with Excess of Blasts
Phase 1: Oncology Solid Tumor Unspecified|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Lymphoid Leukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Preleukemia|Chronic Myeloid Leukemia|Chronic Lymphoid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2013-01665 | P2 |
Completed |
Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia |
2021-01-11 |
|
| AMLSG 24-15 | P2 |
Completed |
Myelodysplastic Syndrome|Preleukemia|Acute Myeloid Leukemia|Anemia, Refractory, with Excess of Blasts |
2019-10-31 |
|
| AMLSG 24-15 | P2 |
Terminated |
Myelodysplastic Syndrome|Acute Myeloid Leukemia |
2019-10-31 |
|
| VITAL | P2 |
Active, not recruiting |
Preleukemia|Acute Myeloid Leukemia|Sarcoma, Myeloid|Myelodysplastic Syndrome |
2019-04-01 |